Research
Print page Print page
Switch language
Bispebjerg Hospital - a part of Copenhagen University Hospital
Published

Improvement in psoriasis after treatment with the glucagon-like peptide-1 receptor agonist liraglutide

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Paradoxical inhibition of insulin secretion by glucose in non-insulin-dependent diabetic patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Permeability of small vessels in diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Management of Ocular Manifestations of Atopic Dermatitis: A Consensus Meeting Using a Modified Delphi Process

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Clinical Management of Atopic Dermatitis in Adults: Mapping of Expert Opinion in 4 Nordic Countries using a Modified Delphi Process

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Tattoos and skin barrier function: Measurements of TEWL, stratum corneum conductance and capacitance, pH, and filaggrin

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Incidence and Risk of Inflammatory Bowel Disease in Patients with Psoriasis-A Nationwide 20-Year Cohort Study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
A 59-year old man with moderate and stable psoriasis through 15 years was admitted to our Department with inadequately controlled type 2 diabetes. Treatment was initiated with the glucagon-like peptide-1 receptor (GLP-1R) agonist liraglutide. The patient experienced marked improvement in his psoriasis immediately after the start of liraglutide treatment. Itching stopped within days, scaling was reduced and spots of normal skin emerged. After 3 months, psoriasis was still improving. Excellent glycaemic control and a weight loss of approximately 8 kg over 3 months were moreover obtained. The patient had previously been well controlled in his diabetes without improvement in psoriasis, and the effect of liraglutide on psoriasis started before weight loss occurred. We discuss the possibility of a direct anti-inflammatory effect of liraglutide in psoriasis as well as indirect effects through improvement in comorbidities such as overweight. Randomized clinical trials are needed to reveal whether GLP-1R agonists represent a new therapeutic option for psoriasis.
Original languageEnglish
JournalActa Diabetologica
ISSN0940-5429
DOIs
Publication statusPublished - 2011

ID: 33133098